Qianwen Liu

651 Dongfeng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.

Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.

Journal: BMC cancer

Published: August 13, 2026

ASO Visual Abstract: Neoadjuvant Chemoimmunotherapy Versus Standard Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

ASO Visual Abstract: Neoadjuvant Chemoimmunotherapy Versus Standard Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Journal: Annals of surgical oncology

Published: August 08, 2026

Neoadjuvant Chemoimmunotherapy Versus Standard Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Neoadjuvant Chemoimmunotherapy Versus Standard Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Journal: Annals of surgical oncology

Published: March 09, 2026

Development and validation of a nomogram for predicting long-term survival in pN + esophageal squamous cell carcinoma treated using radical resection without neoadjuvant therapy.

Development and validation of a nomogram for predicting long-term survival in pN + esophageal squamous cell carcinoma treated using radical resection without neoadjuvant therapy.

Journal: Annals of medicine

Published: November 01, 2025

Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trials.

Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trials.

Journal: Annals of medicine

Published: October 22, 2025

A Pectin-Based Delivery Nanoplatform with an Optimized Tradeoff between Active Targeting and Drug Loading for Hepatocellular Carcinoma Treatment.

A Pectin-Based Delivery Nanoplatform with an Optimized Tradeoff between Active Targeting and Drug Loading for Hepatocellular Carcinoma Treatment.

Journal: Molecular pharmaceutics

Published: August 08, 2025

Magnetic resonance-guided split-course hypo-fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer: A single arm, phase 2 study.

Magnetic resonance-guided split-course hypo-fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer: A single arm, phase 2 study.

Journal: Cancer

Published: August 07, 2025

A prognostic gene model with psychological stress-related genes captures immune activation in breast cancer.

A prognostic gene model with psychological stress-related genes captures immune activation in breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: June 16, 2025

Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK + and ROS1 + non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial.

Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK + and ROS1 + non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial.

Journal: EClinicalMedicine

Published: May 08, 2025

Unraveling Immunotherapy Resistance in Solid Tumors: Decoding Mechanisms and Charting Future Therapeutic Landscapes.

Unraveling Immunotherapy Resistance in Solid Tumors: Decoding Mechanisms and Charting Future Therapeutic Landscapes.

Journal: Oncology research

Published: May 07, 2025

MicroRNA-mediated autophagy regulation in thyroid cancer drug resistance.

MicroRNA-mediated autophagy regulation in thyroid cancer drug resistance.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: April 02, 2025

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 20, 2025

Showing 1-12 of 65

Last Updated: 09/26/2026